Share this page

July 16, 2026

EPS Corporation

“EPS BIOPath”, EPS Launches a New End-to-End Support Service for Biotech Companies Entering Japan
— Providing Collaborative Support in Japan from Development Strategy to Execution —

EPS Corporation (Headquarters: Tokyo; Representative Director: Noriyuki Takai; hereinafter "EPS"), a provider of development support services for pharmaceuticals, medical devices, and regenerative medicine products, has announced the launch of "EPS BIOPath", an integrated consulting service designed to provide side-by-side guidance and support for foreign and Japan domestic biotech companies looking to optimize their entry into the Japanese pharmaceutical development market.
This service is designed to help biotech companies entering the Japanese market or engaged in development in Japan make much efficiently and increase the likelihood of success. It addresses common challenges such as clarifying and structuring development requirements, interpreting regulations, and the gap between strategy and execution by designing strategies rooted in data-driven scientific insights and by providing consistent support from the initial stages of development planning.
Key Features and Value Proposition of This Service

Challenges Addressed

Foreign and Japan domestic biotech companies face a wide range of challenges, including formulating development strategies, fundraising, licensing strategies, and commercialization planning. EPS BIOPath addresses these challenges through data-driven strategic design and comprehensive support from the earliest stages of development, helping them maximize the likelihood of success in entering the Japanese market.


Overview of This Service

Taking a sponsor-centric approach, EPS BIOPath provides integrated and comprehensive consulting across every stage of pharmaceutical development from assisting with the preparation of Requests for Proposals for various partner companies to strategy and planning, regulatory consultations, clinical trial launch, and ultimately, business strategies. By flexibly combining services to match the underlying needs of our clients, we build the optimal strategy to help clients achieve their development goals efficiently.


Social Significance

In recent years, “Drug Lag and Drug Loss”^*2 have been recognized as critical social issues in Japan.
We view contributing to the resolution of these issues as an important responsibility. Behind these challenges are patients waiting for timely access to treatment. Recognizing their urgent needs, we remain committed to helping accelerate access to innovative medicines.
Through EPS BIOPath, we aim to support more efficient and feasible development PATH in Japan for biotech companies, while contributing to efforts to address Drug Lag and Drug Loss. Our ultimate goal is to help ensure that patients and healthcare professionals receive innovative new medicines and treatment options as swiftly as possible.


Future Outlook

EPS has long played a role in connecting medical institutions, patients, and pharmaceutical companies through our comprehensive support for clinical trials and clinical research. Moving forward, through EPS BIOPath, we will provide even more flexible and highly effective support and proposals, specifically tailored for foreign and domestic biotech companies aiming to develop products in the Japanese market. By doing so, we will further contribute to enhancing Japan’s drug development environment and resolving Drug Lag and Drug Loss, ensuring that new treatment options reach patients and healthcare professionals as swiftly as possible.


About EPS Corporation

EPS Corporation began operations in 1991 and is a leading CRO^*3 that provides comprehensive support for clinical trials and clinical research, with a focus on clinical development and post-marketing surveillance. The company proposes new models to meet customers’ needs by leveraging its data science expertise and digital technologies cultivated through its extensive track record. These service offerings are anchored in its Trial GATE concept, which acts as the gateway for all clinical trial functions.

For media inquiries or further information, please contact:

EPS Corporation
Public Relations Department
E-mail: koho@eps.co.jp

※1 CMC：Chemistry, Manufacturing and Controls
※2 Drug Lag and Drug Loss：Delayed access to innovative medicines or unavailability of new therapies
※3 CRO：Contract Research Organization